Data from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

MLA

Philip D. Dunne, et al. Data from In-Depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6530324.v1.

APA

Philip D. Dunne, Louise C. Brown, Timothy S. Maughan, Mark Lawler, Daniel B. Longley, Richard S. Kaplan, Letitia Campo, Viktor H. Koelzer, Ian Tomlinson, Patrick G. Johnston, Richard D. Kennedy, Manuel Salto-Tellez, Nicholas P. West, Philip Quirke, Dion G. Morton, Matthew T. Seymour, Ultan McDermott, Stephanie G. Craig, Matthew P. Humphries, … Sudhir B. Malla. (2023). Data from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. https://doi.org/10.1158/1078-0432.c.6530324.v1

Chicago

Philip D. Dunne, Louise C. Brown, Timothy S. Maughan, Mark Lawler, Daniel B. Longley, Richard S. Kaplan, Letitia Campo, et al. 2023. “Data from In-Depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer,” March. doi:10.1158/1078-0432.c.6530324.v1.